What it is
Semax is a synthetic peptide, a modified fragment of the natural hormone ACTH (adrenocorticotropic hormone). The core sequence corresponds to ACTH(4-7), with a Pro-Gly-Pro tail added to the end. That tail is the clever part: it blocks the enzymes that would normally chew the peptide up in seconds, which lets the molecule survive long enough to act and to cross from the nasal passage toward the brain.
It was developed in Russia in the 1980s. In Russia it is an approved medicine, listed for ischemic stroke recovery and cognitive impairment. It is not approved by the FDA, the EMA, the MHRA, or any other Western regulator. Almost all of the clinical literature is Russian and has not been replicated in large Western randomised trials.
Semax is a peptide (a short chain of amino acids), not a hormone you are dosing for muscle and not a stimulant.
What people use it for
People use Semax mainly as a nootropic, meaning for focus, mental stamina, memory, and a general feeling of mental clarity. The most mechanistically interesting claim is that it raises BDNF (brain-derived neurotrophic factor) and its receptor in the hippocampus, which is plausibly tied to its cognitive and neuroprotective reputation. In Russia its formal medical use is in stroke recovery and other neurological settings, not in healthy biohackers.
Be clear with yourself about the gap between “approved in one country for stroke” and “proven safe and effective for a healthy person who wants to study harder.” Those are not the same claim.
Typical dose range
Reported nootropic use is commonly in the range of 600 to 1,200 mcg per day intranasally, often split into smaller doses across the day, using a 0.1 percent solution. The much higher doses you may see (9,000 to 18,000 mcg/day via a 1 percent solution) come from acute stroke protocols in a hospital setting and are not a recreational starting point.
If you are working with dosing, a reconstitution and dosing calculator is here: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Conservative practice is to start at the low end, assess tolerance, and not assume more is better. The human data does not support chasing high doses for cognition.
Half-life and frequency
The plasma half-life of Semax is short, on the order of minutes. Despite that, reported effects last far longer than the blood level would suggest, which is the usual fingerprint of a peptide that works by changing gene expression (for example BDNF) rather than by sitting on a receptor all day. In practice this is why protocols dose one to a few times per day rather than relying on a single dose to last.
How it is taken (oral vs injectable, reconstitution if relevant)
Semax is almost always used intranasally, as drops or a spray. Nasal delivery is the point: it is how the molecule is thought to reach the brain efficiently. A subcutaneous injectable form also exists and is used by some, but nasal is the standard and best-studied route.
If you are reconstituting a lyophilised (freeze-dried) powder into a nasal solution, bacteriostatic water is the usual diluent and the concentration determines how many micrograms each drop or spray delivers. Work the numbers before dosing: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Storage
Lyophilised peptide is most stable kept frozen or refrigerated and away from light. Once reconstituted, keep the solution refrigerated and treat it as having a limited shelf life (typically weeks, not months). Discard if it becomes cloudy, discoloured, or develops particulates. Nasal solutions in particular can degrade and can grow contaminants, so do not stretch an old vial.
Common side effects
Across the Russian clinical literature Semax is reported as well tolerated, and many trials report no side effects. The most commonly noted issue is mild nasal irritation from the spray. Less frequently reported items include nasal discoloration and small changes in blood glucose. Some users report headache or feeling overstimulated, especially at higher doses.
The honest caveat: “well tolerated in short Russian trials” is not the same as “proven safe for daily long-term use in the general population.” Long-term safety data outside Russia is thin.
Evidence grade
Moderate mechanistic evidence, weak-to-moderate clinical evidence for cognition in healthy people.
There is a real and fairly deep body of Russian research, including animal mechanism work (notably on BDNF) and human use in stroke and cognitive impairment. What is missing is independent, large, randomised, placebo-controlled Western replication, especially for the “healthy person wants to focus” use case. So the mechanism story is more credible than for most marketed nootropics, but the clinical proof for everyday cognitive enhancement is not strong.
Honest unknowns
- Long-term safety of daily use in healthy adults is not well characterised.
- Effect sizes for cognition in healthy (non-patient) users are unclear and likely modest.
- Optimal dose, frequency, and cycling are not settled by good data; common protocols are convention, not proof.
- Product quality varies. Research-grade peptides are not pharmaceuticals and purity, sterility, and actual content can differ from the label.
- Most evidence is in one language and one research tradition, which limits independent scrutiny.
Research use only. Not medical advice. 18+.